According to results of the ADVANCE and MOTIVATE phase 3 induction studies, Skyrizi (risankizumab, AbbVie), an anti-interleukin-23 75 p19 monoclonal antibody, outperformed placebo in clinical ...
The new results, reported at the American Academy of Dermatology annual meeting, suggest that Skyrizi (risankizumab) treatment could be used to ‘rescue’ patients with moderate to severe ...
Skyrizi (risankizumab) is the first IL-23-selective drug to be cleared for the inflammatory bowel disease – ahead of rivals like Johnson & Johnson's Tremfya (guselkumab), and Sun Pharma's Ilumya ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback